Effect of Methylprednisolone on Complement Activation in Patients Undergoing Total Knee-arthroplasty
Effect of Preoperative Intravenous High Dose Methylprednisolone on Complement Activation in Patients Scheduled for Total Knee-arthroplasty
1 other identifier
interventional
70
1 country
1
Brief Summary
This study evaluates the pathophysiological effects of a single dose of methylprednisolone administered prior to total knee-arthroplasty surgery. The investigators examine the effect on complement activation. Half of participants will receive intravenous Solu-Medrol 125 mg, while the other half will receive placebo. The investigators hypothesize that the group receiving methylprednisolone will experience beneficial inhibition of the undesirable parts of the complement activation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Jan 2015
Shorter than P25 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2015
CompletedFirst Submitted
Initial submission to the registry
January 5, 2015
CompletedFirst Posted
Study publicly available on registry
January 7, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2016
CompletedApril 8, 2016
April 1, 2016
1.2 years
January 5, 2015
April 7, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in plasma and serum Pentraxin-3 concentrations from baseline (before surgery) to 48 hours after surgery
baseline to 48 hours
Secondary Outcomes (5)
Change in plasma and serum Complement Component 3 concentrations from baseline (before surgery) to 48 hours after surgery
baseline to 48 hours
Change in plasma and serum Complement Component 4 concentrations from baseline (before surgery) to 48 hours after surgery
baseline to 48 hours
Change in plasma and serum Mannose-binding lectin concentrations from baseline (before surgery) to 48 hours after surgery
baseline to 48 hours
Change in plasma and serum Ficolin-1, -2 and -3 concentrations from baseline (before surgery) to 48 hours after surgery
baseline to 48 hours
Change in plasma and serum Terminal Complement Complex concentrations from baseline (before surgery) to 48 hours after surgery
baseline to 48 hours
Study Arms (2)
Methylprednisolone
ACTIVE COMPARATORPreoperative single high dose of Solu-Medrol 125 mg iv.
Isotonic Sodium Chloride
PLACEBO COMPARATORPreoperative single dose of isotonic Sodium Chloride
Interventions
Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
Eligibility Criteria
You may qualify if:
- Osteoarthrosis
- Undergoing total unilateral knee-arthroplasty surgery
- Speak and understand Danish
- Have given informed consent
You may not qualify if:
- Revision, bilateral or uni chamber knee-arthroplasty surgery
- General anaesthesia
- Allergy or intolerance towards Methylprednisolone
- Local or systemic infection
- Permanent systemic treatment with steroids within 30 days preoperatively
- Insulin-dependent diabetes
- Active treatment of ulcer within 3 months preoperatively
- Cancer disease
- Autoimmune disease incl. rheumatoid arthritis
- Pregnant or breast feeding women
- Menopause \<1 year
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rigshospitalet, Denmarklead
- Bispebjerg Hospitalcollaborator
Study Sites (1)
Bispebjerg Hospital
Copenhagen NV, 2400, Denmark
Related Publications (8)
Husted H. Fast-track hip and knee arthroplasty: clinical and organizational aspects. Acta Orthop Suppl. 2012 Oct;83(346):1-39. doi: 10.3109/17453674.2012.700593.
PMID: 23205862BACKGROUNDKehlet H. Fast-track hip and knee arthroplasty. Lancet. 2013 May 11;381(9878):1600-2. doi: 10.1016/S0140-6736(13)61003-X. No abstract available.
PMID: 23663938BACKGROUNDKhan SK, Malviya A, Muller SD, Carluke I, Partington PF, Emmerson KP, Reed MR. Reduced short-term complications and mortality following Enhanced Recovery primary hip and knee arthroplasty: results from 6,000 consecutive procedures. Acta Orthop. 2014 Feb;85(1):26-31. doi: 10.3109/17453674.2013.874925. Epub 2013 Dec 20.
PMID: 24359028BACKGROUNDMalviya A, Martin K, Harper I, Muller SD, Emmerson KP, Partington PF, Reed MR. Enhanced recovery program for hip and knee replacement reduces death rate. Acta Orthop. 2011 Oct;82(5):577-81. doi: 10.3109/17453674.2011.618911. Epub 2011 Sep 6.
PMID: 21895500BACKGROUNDAbdelmalak BB, Bonilla AM, Yang D, Chowdary HT, Gottlieb A, Lyden SP, Sessler DI. The hyperglycemic response to major noncardiac surgery and the added effect of steroid administration in patients with and without diabetes. Anesth Analg. 2013 May;116(5):1116-1122. doi: 10.1213/ANE.0b013e318288416d. Epub 2013 Apr 4.
PMID: 23558840BACKGROUNDMurphy GS, Szokol JW, Avram MJ, Greenberg SB, Shear T, Vender JS, Gray J, Landry E. The effect of single low-dose dexamethasone on blood glucose concentrations in the perioperative period: a randomized, placebo-controlled investigation in gynecologic surgical patients. Anesth Analg. 2014 Jun;118(6):1204-12. doi: 10.1213/ANE.0b013e3182a53981.
PMID: 24299928BACKGROUNDde la Motte L, Kehlet H, Vogt K, Nielsen CH, Groenvall JB, Nielsen HB, Andersen A, Schroeder TV, Lonn L. Preoperative methylprednisolone enhances recovery after endovascular aortic repair: a randomized, double-blind, placebo-controlled clinical trial. Ann Surg. 2014 Sep;260(3):540-8; discussion 548-9. doi: 10.1097/SLA.0000000000000895.
PMID: 25115430BACKGROUNDDieleman JM, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, Schepp RM, Boer C, Moons KG, van Herwerden LA, Tijssen JG, Numan SC, Kalkman CJ, van Dijk D; Dexamethasone for Cardiac Surgery (DECS) Study Group. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA. 2012 Nov 7;308(17):1761-7. doi: 10.1001/jama.2012.14144.
PMID: 23117776BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Viktoria Lindberg-Larsen, MD
Section for Surgical Pathophysiology, Rigshospitalet
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, research assistant
Study Record Dates
First Submitted
January 5, 2015
First Posted
January 7, 2015
Study Start
January 1, 2015
Primary Completion
April 1, 2016
Study Completion
April 1, 2016
Last Updated
April 8, 2016
Record last verified: 2016-04